secwatch.observer — SEC 8-K summary
======================================

Issuer:     Profound Medical Corp. (PROF)
CIK:        0001628808
Form:       8-K
Filed at:   2025-03-07T23:59:59+00:00
Accession:  0001171843-25-001319
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 2.03, 4.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Profound Medical restates Q1-Q3 2024 financials due to $472k revenue error; Q4 revenue up 108% YoY
--------------------------------------------------------------------------------

- Revenue overstated by $472k in Q1 2024; prior 6-K filings for Q1-Q3 2024 no longer reliable.
- Q4 2024 revenue $4.2M (+108% YoY); net loss $4.9M ($0.20/share) vs $8.9M ($0.42) in Q4 2023.
- Full year 2024 revenue $10.7M; net loss $27.8M ($1.12/share) vs $28.3M ($1.34) in 2023.
- New $10M CIBC revolving credit line matures March 2027; option to increase to $15M if trailing revenue exceeds $15M.
- Mathieu Burtnyk promoted to President; Tom Tamberrino appointed CCO; CAPTAIN trial enrollment complete.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628808/000117184325001319/0001171843-25-001319-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628808/000117184325001319/f8k_030725.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-001319

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer